Author:
Gulley James L.,Arlen Philip M.,Madan Ravi A.,Tsang Kwong-Yok,Pazdur Mary P.,Skarupa Lisa,Jones Jacquin L.,Poole Diane J.,Higgins Jack P.,Hodge James W.,Cereda Vittore,Vergati Matteo,Steinberg Seth M.,Halabi Susan,Jones Elizabeth,Chen Clara,Parnes Howard,Wright John J.,Dahut William L.,Schlom Jeffrey
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference33 articles.
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin l59:225–249
2. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol l21:1232–1237
3. Corman JSE, Smith D et al (2006) Immunotherapy with GVAX® vaccine for prostate cancer improves predicted survival in metastatic hormone refractory prostate cancer: results from two phase 2 studies [abstract 976]. In: Proceedings of the American Urological Association Annual Meeting, Atlanta, GA
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med l351:1502–1512
5. Schellhammer PF, Higano C, Berger ER, Shore N, Small E, Penson D, Ferrari A, Sims R, Yuh L, Frohlich M, Kantoff P, for the IMPACT Study Investigators (2009) A randomized, double-blind, placebo-controlled multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract]. In: American Urological Association Annual Meeting. 25–30 April 2009, Chicago, IL
Cited by
263 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献